On 13 th of September 2019, the U.S. Food and Drug Administration (USFDA) issued an alert indicating low levels of N-nitrosodimethylamine (NMDA) in the popular drug Ranitidine; thereby recommending health care professionals and patients to a voluntary recall Ranitidin e medication. 1,2 Ranitidine is an antacid used to reduce stomach acids and ulcers. In several countries, the drug is available over the counter at pharmacies and is usually prescribed by doctors.
NMDA; the traces of the impurity found in Ranitidine, has been classified by the International Agency for Research on Cancer as probably carcinogenic to humans and may also cause liver damage and low platelet counts. However, its actual effects on humans have not been discovered, yet. 1 Following the FDA alert, several prominent drug makers have recalled their editions of the drug in some markets. 3 However, many smaller players,…
